<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747067</url>
  </required_header>
  <id_info>
    <org_study_id>HD vs HDF</org_study_id>
    <nct_id>NCT04747067</nct_id>
  </id_info>
  <brief_title>To Assess the Effect of HDF Versus High Flux Dialysis on Free Light Chains and Cumulative Albumin Loss, in End Stage Renal Disease Patients.</brief_title>
  <official_title>The Effect of Hemodiafiltration Versus High Flux Dialysis On Free Light Chains Reduction And Its Relation To Albumin Loss.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Removal of uremic toxins is the main goal of HD, It was improved by using high volume&#xD;
      convective technique with high flux dialyzer. This technique removes medium - large molecular&#xD;
      weight solutes giving higher dialysis adequacy and consequently improving the quality of&#xD;
      life.&#xD;
&#xD;
      This study will assess the effect of hemodiafiltration (HDF) versus high flux dialysis on&#xD;
      free light chains (FLC) reduction as a marker of HD adequacy and its relation to albumin&#xD;
      loss.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>free light chain reduction ratio</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Measurement of kappa and lambda free light chains pre and post dialysis sessions, in patients undergoing high flux dialysis versus HDF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High sensitive C- reactive protein reduction ratio (HsCRP)</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Measuring of high sensitive C-reactive protein pre and post dialysis sessions, in patients undergoing high flux dialysis versus HDF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative albumin loss</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Assessment of cumulative albumin loss by measuring albumin spent in dialysate -hourly- in patients undergoing high flux dialysis versus HDF</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Hemodiafiltration</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>High flux HD</arm_group_label>
    <description>measuring free light chains (Kappa and lambda) reduction ratio , hsCRP reduction ratio and cumulative albumin loss on patients undergoing high flux hemodialysis session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDF</arm_group_label>
    <description>measuring free light chains (Kappa and lambda) reduction ratio , hsCRP reduction ratio and cumulative albumin loss on patients undergoing hemodiafiltration session.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be withdrawn from the arterial line at the beginning of the midweek&#xD;
      dialysis session.&#xD;
&#xD;
      Complete blood count. Routine chemistry (S. creatinine, Blood Urea Nitrogen , S. Sodium and&#xD;
      S. potassium, Corrected s. calcium, phosphate).&#xD;
&#xD;
      Parathyroid hormone (PTH). Free light chains (kappa and Lambda) with ELISA technique will be&#xD;
      done to all patients before and after the dialysis session.&#xD;
&#xD;
      HsCRP will be done to all patients before and after sessions.&#xD;
&#xD;
      Albumin:&#xD;
&#xD;
      Albumin samples will be collected from the spent dialysate throughout the dialysis session;&#xD;
      after half, 1st,2nd ,3rd hour and at the end of the dialysis session to estimate the&#xD;
      cumulative albumin loss.&#xD;
&#xD;
      Serum albumin will also be measured for all patients.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants of this study are ESRD patients on regular hemodialysis ,for more than 6&#xD;
        months. From Ain Shams University dialysis units.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prevalent HD patients on regular hemodialysis sessions for &gt;6 months 3 sessions/week&#xD;
             of 4 hours duration.&#xD;
&#xD;
          -  Patients with Arterio-venous fistula as dialysis access.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hemodialysis catheters.&#xD;
&#xD;
          -  Patients with active inflammation or infection.&#xD;
&#xD;
          -  Decompensated heart failure.&#xD;
&#xD;
          -  Liver Cell Failure ( Child B,C)&#xD;
&#xD;
          -  Patients with known malignancies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reem Sultan, M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Ain Shams Univeristy.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hesham ElSayed, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, Ain Shams Univeristy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magdy ElSharkawy, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, Ain Shams Univeristy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waleed AbdelMohsen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Ain Shams Univeristy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shaimaa Zaki, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Ain Shams Univeristy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Emara, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Ain Shams Univeristy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reem Sultan, M.Sc</last_name>
    <phone>01004096789</phone>
    <email>reemsultan@live.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <state>Governorate</state>
        <zip>0000</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reem Sultan</last_name>
      <phone>01004096789</phone>
      <email>reemsultan@live.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Bourguignon C, Chenine L, Bargnoux AS, Leray-Moragues H, Canaud B, Cristol JP, Morena M. Hemodiafiltration improves free light chain removal and normalizes κ/λ ratio in hemodialysis patients. J Nephrol. 2016 Apr;29(2):251-257. doi: 10.1007/s40620-015-0207-z. Epub 2015 May 29.</citation>
    <PMID>26022721</PMID>
  </reference>
  <reference>
    <citation>Donati G, Moretti MI, Baraldi O, Spazzoli A, Capelli I, Comai G, Marchetti A, Sarma M, Mancini R, La Manna G. Removal of free light chains in hemodialysis patients without multiple myeloma: a crossover comparison of three different dialyzers. BMC Nephrol. 2016 Nov 25;17(1):193.</citation>
    <PMID>27884120</PMID>
  </reference>
  <reference>
    <citation>Lamy T, Henri P, Lobbedez T, Comby E, Ryckelynck JP, Ficheux M. Comparison between on-line high-efficiency hemodiafiltration and conventional high-flux hemodialysis for polyclonal free light chain removal. Blood Purif. 2014;37(2):93-8. doi: 10.1159/000357968. Epub 2014 Mar 1.</citation>
    <PMID>24603634</PMID>
  </reference>
  <reference>
    <citation>Maduell F. Hemodiafiltration versus conventional hemodialysis: Should &quot;conventional&quot; be redefined? Semin Dial. 2018 Nov;31(6):625-632. doi: 10.1111/sdi.12715. Epub 2018 May 29. Review.</citation>
    <PMID>29813181</PMID>
  </reference>
  <reference>
    <citation>Nagai K, Tsuchida K, Ishihara N, Minagawa N, Ichien G, Yamada S, Hirose D, Michiwaki H, Kanayama HO, Doi T, Minakuchi J. Implications of Albumin Leakage for Survival in Maintenance Hemodialysis Patients: A 7-year Observational Study. Ther Apher Dial. 2017 Aug;21(4):378-386. doi: 10.1111/1744-9987.12526. Epub 2017 Apr 27.</citation>
    <PMID>28452109</PMID>
  </reference>
  <reference>
    <citation>van Gelder MK, Abrahams AC, Joles JA, Kaysen GA, Gerritsen KGF. Albumin handling in different hemodialysis modalities. Nephrol Dial Transplant. 2018 Jun 1;33(6):906-913. doi: 10.1093/ndt/gfx191. Review.</citation>
    <PMID>29106652</PMID>
  </reference>
  <reference>
    <citation>Wolley M, Jardine M, Hutchison CA. Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules. Clin J Am Soc Nephrol. 2018 May 7;13(5):805-814. doi: 10.2215/CJN.10110917. Epub 2018 Mar 5. Review.</citation>
    <PMID>29507008</PMID>
  </reference>
  <reference>
    <citation>Wolley MJ, Hutchison CA. Large uremic toxins: an unsolved problem in end-stage kidney disease. Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii6-iii11. doi: 10.1093/ndt/gfy179. Review.</citation>
    <PMID>30281131</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 6, 2021</study_first_submitted>
  <study_first_submitted_qc>February 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Reem Sultan</investigator_full_name>
    <investigator_title>Assistant lecturer of Internal Medicine and Nephrology</investigator_title>
  </responsible_party>
  <keyword>End stage renal disease (ESRD)</keyword>
  <keyword>hemodiafiltration (HDF)</keyword>
  <keyword>hemodialysis (HD)</keyword>
  <keyword>Free light chains</keyword>
  <keyword>Albumin loss</keyword>
  <keyword>Kappa and lambda</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

